Deleting DNMT3A in CAR T cells prevents exhaustion and enhances antitumor activity

Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles

Subramanian, A., Tamayo, P., Mootha, V. K., Mukherjee, S., Ebert, B. L., Gillette, M. A., Paulovich, A., Pomeroy, S. L., Golub, T. R., Lander, E. S., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506580102 · Cited by 53,625

<tt>edgeR</tt> : a Bioconductor package for differential expression analysis of digital gene expression data

Robinson, M. D., McCarthy, D. J., & Smyth, G. K. (2010) · Bioinformatics · doi:10.1093/bioinformatics/btp616 · Cited by 41,364

limma powers differential expression analyses for RNA-sequencing and microarray studies

Ritchie, M. E., Phipson, B., Wu, D., Hu, Y., Law, C. W., Shi, W., & Smyth, G. K. (2015) · Nucleic Acids Research · doi:10.1093/nar/gkv007 · Cited by 40,458

ggplot2

Wickham, H. (2016) · Use R! · doi:10.1007/978-3-319-24277-4 · Cited by 34,873

Integrative genomics viewer

Robinson, J. T., Thorvaldsdóttir, H., Winckler, W., Guttman, M., Lander, E. S., Getz, G., & Mesirov, J. P. (2011) · Nature Biotechnology · doi:10.1038/nbt.1754 · Cited by 15,390

ggplot2: Elegant Graphics for Data Analysis

Wickham, H. (2009) · doi:10.1007/978-0-387-98141-3 · Cited by 14,447

Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia

Maude, S. L., Laetsch, T. W., Buechner, J., Rives, S., Boyer, M., Bittencourt, H., Bader, P., Verneris, M. R., Stefanski, H. E., Myers, G. D., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1709866 · Cited by 5,735

Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia

Maude, S. L., Frey, N., Shaw, P. A., Aplenc, R., Barrett, D. M., Bunin, N. J., Chew, A., Gonzalez, V. E., Zheng, Z., Lacey, S. F., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1407222 · Cited by 5,413

Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia

Park, J. H., Rivière, I., Gonen, M., Wang, X., Sénéchal, B., Curran, K. J., Sauter, C., Wang, Y., Santomasso, B., Mead, E., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1709919 · Cited by 2,688

Machine Learning Identifies Stemness Features Associated with Oncogenic Dedifferentiation

Malta, T. M., Sokolov, A., Gentles, A. J., Burzykowski, T., Poisson, L., Weinstein, J. N., Kamińska, B., Huelsken, J., Omberg, L., Gevaert, O., et al. (2018) · Cell · doi:10.1016/j.cell.2018.03.034 · Cited by 2,180

Hematopoietic-specific heterozygous loss of Dnmt3a exacerbates colitis-associated colon cancer

Feng, Y., Yuan, Q., Newsome, R. C., Robinson, T. M., Bowman, R. L., Zuniga, A. N., Hall, K. N., Bernsten, C. M., Shabashvili, D. E., Krajcik, K. I., et al. (2023) · The Journal of Experimental Medicine · doi:10.1084/jem.20230011 · Cited by 30

mRNA-based therapeutic strategies for cancer treatment

Taibi, T., Cheon, S., Perna, F., & Vu, L. (2024) · Molecular Therapy · doi:10.1016/j.ymthe.2024.04.035 · Cited by 31

IL-18R supported CAR T cells targeting oncofetal tenascin C for the immunotherapy of pediatric sarcoma and brain tumors

Wickman, E., Lange, S., Wagner, J., Ibañez-Vega, J., Tian, L., Lu, M., Sheppard, H., Chiang, J., Koo, S. C., Vogel, P., et al. (2024) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2024-009743 · Cited by 27

Empowering the Potential of CAR-T Cell Immunotherapies by Epigenetic Reprogramming

Alvanou, M., Lysandrou, M., Christofi, P., Psatha, N., Spyridonidis, A., Παπαδοπούλου, Α., & Yannaki, E. (2023) · Cancers · doi:10.3390/cancers15071935 · Cited by 28

CAR T-cell Design-dependent Remodeling of the Brain Tumor Immune Microenvironment Modulates Tumor-associated Macrophages and Anti-glioma Activity

Haydar, D., Ibañez-Vega, J., Crawford, J. C., Chou, C., Guy, C. S., Meehl, M. M., Yi, Z., Perry, S., Laxton, J., Cunningham, T., et al. (2023) · Cancer Research Communications · doi:10.1158/2767-9764.crc-23-0424 · Cited by 28

The crossroads of cancer therapies and clonal hematopoiesis

Singh, A., & Balasubramanian, S. K. (2024) · Seminars in Hematology · doi:10.1053/j.seminhematol.2024.01.006 · Cited by 28

Cancer epigenetic therapy: recent advances, challenges, and emerging opportunities

Vatapalli, R. J., Rossi, A. P., Chan, H. M., & Zhang, J. (2024) · Epigenomics · doi:10.1080/17501911.2024.2430169 · Cited by 28

CAR T Cell Immunotherapy Beyond Haematological Malignancy

Hupperetz, C., Lah, S., Kim, H., & Kim, C. H. (2022) · Immune Network · doi:10.4110/in.2022.22.e6 · Cited by 26

Safety, Outcomes, and T-Cell Characteristics in Patients with Relapsed or Refractory MDS or CMML Treated with Atezolizumab in Combination with Guadecitabine

O'Connell, C. L., Baer, M. R., Ørskov, A. D., Saini, S. K., Duong, V. H., Kropf, P. L., Hansen, J. W., Tsao-Wei, D. D., Jang, H. J., Emadi, A., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-1810 · Cited by 26

Targeting Driver Oncogenes and Other Public Neoantigens Using T Cell Receptor–Based Cellular Therapy

Martinov, T., & Greenberg, P. D. (2023) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-061521-082114 · Cited by 27

Genetic engineering strategies to enhance antitumor reactivity and reduce alloreactivity for allogeneic cell-based cancer therapy

Chen, Y., Zhu, Y., Kramer, A. B., Fang, Y., Wilson, M., Li, Y.-R., & Yang, L. (2023) · Frontiers in Medicine · doi:10.3389/fmed.2023.1135468 · Cited by 26

Advancing CAR T-cell therapies: Preclinical insights and clinical translation for hematological malignancies

Arunachalam, A. K., Grégoire, C., de Oliveira, B. C., & Melenhorst, J. J. (2024) · Blood Reviews · doi:10.1016/j.blre.2024.101241 · Cited by 27

T Cell Exhaustion in Cancer Immunotherapy: Heterogeneity, Mechanisms, and Therapeutic Opportunities

Yang, Y. P., Yao, X., Wang, Q., Yang, M., Li, R., Qin, J., Zhuang, J., & Sun, C. (2026) · Advanced Science · doi:10.1002/advs.202520634 · Cited by 27

T cell exhaustion and senescence for ovarian cancer immunotherapy

Zhao, J., Wang, Z., Tian, Y., Ning, J., & Ye, H. (2024) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2024.07.001 · Cited by 26

Degradation of IKZF1 prevents epigenetic progression of T cell exhaustion in an antigen-specific assay

Tay, T., Bommakanti, G., Jaensch, E. S., Gorthi, A., Reddy, I. K., Hu, Y., Zhang, R., Doshi, A. S., Tan, S. L., Brucklacher-Waldert, V., et al. (2024) · Cell Reports Medicine · doi:10.1016/j.xcrm.2024.101804 · Cited by 23

Next-generation T cell immunotherapies engineered with CRISPR base and prime editing: challenges and opportunities

Petri, K., D’Ippolito, E., Künkele, A., Koehl, U., Busch, D. H., Einsele, H., & Hudecek, M. (2025) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-025-01072-4 · Cited by 28

Decitabine in combination with fludarabine and cyclophosphamide as a lymphodepletion regimen followed by CD19/CD22 bispecific targeted CAR T-cell therapy significantly improves survival in relapsed/refractory B-ALL patients

Ma, Y., Dai, H., Cui, Q., Liu, S., Kang, L., Lian, X., Cui, W., Yin, J., Liu, L., Cai, M., et al. (2023) · Experimental Hematology and Oncology · doi:10.1186/s40164-023-00397-z · Cited by 23

Genome Editing in Engineered T Cells for Cancer Immunotherapy

Bonini, C., Chapuis, A. G., Hudecek, M., Guedan, S., Magnani, C. F., & Qasim, W. (2023) · Human Gene Therapy · doi:10.1089/hum.2023.128 · Cited by 29

Epigenetic profiles guide improved CRISPR/Cas9-mediated gene knockout in human T cells

Ito, Y., Inoue, S., Nakashima, T., Zhang, H., Li, Y., Kasuya, H., Matsukawa, T., Wu, Z., Yoshikawa, T., Kataoka, M., et al. (2023) · Nucleic Acids Research · doi:10.1093/nar/gkad1076 · Cited by 23

From Multi‐Omics to Visualization and Beyond: Bridging Micro and Macro Insights in CAR‐T Cell Therapy

Gong, Y., Fei, P., Zhang, Y., Xu, Y., & Wei, J. (2025) · Advanced Science · doi:10.1002/advs.202501095 · Cited by 25

Epigenetic regulation of CD8+ T cell exhaustion: recent advances and update

Li, C., Yuan, Y., Jiang, X., & Wang, Q. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1700039 · Cited by 27

CAR T cell persistence in cancer

Mueller, K. P., Grenier, J. M., & Weber, E. W. (2025) · Trends in cancer · doi:10.1016/j.trecan.2025.08.014 · Cited by 22

CHIPing away the progression potential of CHIP: A new reality in the making

Xie, Z., & Zeidan, A. M. (2022) · Blood Reviews · doi:10.1016/j.blre.2022.101001 · Cited by 22

Expanding the frontier of CAR therapy: comparative insights into CAR-T, CAR-NK, CAR-M, and CAR-DC approaches

Zhang, Y., Hu, R., Xie, X., & Li, Y. (2025) · Annals of Hematology · doi:10.1007/s00277-025-06538-0 · Cited by 23

Treatment with Exogenously Added Catalase Alters CD8 T Cell Memory Differentiation and Function

Aksoylar, H., & Patsoukis, N. (2022) · Advanced Biology · doi:10.1002/adbi.202101320 · Cited by 20

Immunometabolite L-2-HG promotes epigenetic modification of exhausted T cells and improves antitumor immunity

Yang, Y., Li, X., Liu, F., Ma, M., Yang, Y., Ruan, C., Lü, Y., Li, X., Wang, X., Shi, Y., et al. (2025) · JCI Insight · doi:10.1172/jci.insight.174600 · Cited by 19

CAR-T cell therapy in brain malignancies: obstacles in the face of cellular trafficking and persistence

Yaacoub, S., VanNoy, E. L., Maslova, S., Haffey, A., Khorsandi, K., Sheybani, N., & Haydar, D. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1596499 · Cited by 19

Challenges and optimal strategies of CAR T therapy for hematological malignancies

Zhang, Y., Yang, X., Dang, X., Zhu, Z., Qian, W., Liang, A., & Han, W. (2023) · Chinese Medical Journal · doi:10.1097/cm9.0000000000002476 · Cited by 19

Development of a microfluidic cell transfection device into gene-edited CAR T cell manufacturing workflow

Yu, T., Jhita, N., Shankles, P. G., Fedanov, A., Kramer, N. B., Raikar, S. S., & Sulchek, T. (2023) · Lab on a Chip · doi:10.1039/d3lc00311f · Cited by 19

Significance of targeting DNMT3A mutations in AML

Huang, G., Cai, X., & Li, D. (2024) · Annals of Hematology · doi:10.1007/s00277-024-05885-8 · Cited by 20

Selective control of transposable element expression during T cell exhaustion and anti–PD-1 treatment

Bonté, P., Metoikidou, C., Heurtebise-Chrétien, S., Arribas, Y. A., Galy, A. S. D., Ye, M., Niborski, L. L., Zueva, E., Piaggio, E., Seguin‐Givelet, A., et al. (2023) · Science Immunology · doi:10.1126/sciimmunol.adf8838 · Cited by 19

Inflammation in myelodysplastic syndrome pathogenesis

Rodríguez‐Sevilla, J. J., & Colla, S. (2024) · Seminars in Hematology · doi:10.1053/j.seminhematol.2024.09.005 · Cited by 20

Clonal hematopoiesis in myeloid malignancies and solid tumors

Cai, X., Bowman, R. L., & Trowbridge, J. J. (2025) · Nature Cancer · doi:10.1038/s43018-025-01014-0 · Cited by 18

Focus on T cell exhaustion: new advances in traditional Chinese medicine in infection and cancer

Li, S., Hao, L., Zhang, J., Deng, J., & Hu, X. (2023) · Chinese Medicine · doi:10.1186/s13020-023-00785-x · Cited by 17

High-plex spatial transcriptomic profiling reveals distinct immune components and the HLA class I/DNMT3A/CD8 modulatory axis in mismatch repair-deficient endometrial cancer

Guo, J., Tang, B., Fu, J., Zhu, X., Xie, W.-L., Wang, N., Ding, Z., Song, Z., Yang, Y., Xu, G., et al. (2023) · Cellular Oncology · doi:10.1007/s13402-023-00885-8 · Cited by 17

Genetic retargeting of E3 ligases to enhance CAR T cell therapy

Lane, I. C., Kembuan, G. J., Carreiro, J., Kann, M. C., Lin, W. M., Bouffard, A. A., Kreuzer, J., Morris, R. T., Schneider, E. M., Kim, J. Y., et al. (2023) · Cell chemical biology · doi:10.1016/j.chembiol.2023.10.024 · Cited by 17

DNAJB1-PRKACA fusion neoantigens elicit rare endogenous T cell responses that potentiate cell therapy for fibrolamellar carcinoma

Kirk, A. M., Crawford, J. C., Chou, C., Guy, C. S., Pandey, K., Kozlik, T., Shah, R. K., Chung, S., Nguyen, P., Zhang, X., et al. (2024) · Cell Reports Medicine · doi:10.1016/j.xcrm.2024.101469 · Cited by 18

Donor T cell DNMT3a regulates alloreactivity in mouse models of hematopoietic stem cell transplantation

Ktena, Y. P., Koldobskiy, M. A., Barbato, M. I., Fu, H.-H., Luznik, L., Llosa, N. J., Haile, A., Klein, O. R., Liu, C., Gamper, C. J., et al. (2022) · Journal of Clinical Investigation · doi:10.1172/jci158047 · Cited by 17

CRISPR-Cas gene knockouts to optimize engineered T cells for cancer immunotherapy

Castro, V. D., Galaine, J., Loyon, R., & Godet, Y. (2024) · Cancer Gene Therapy · doi:10.1038/s41417-024-00771-x · Cited by 18

Fully equipped CARs to address tumor heterogeneity, enhance safety, and improve the functionality of cellular immunotherapies

Alviano, A. M., Biondi, M., Grassenis, E., Biondi, A., Serafini, M., & Tettamanti, S. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1407992 · Cited by 16

Adoptive Cell Therapy in Pediatric and Young Adult Solid Tumors: Current Status and Future Directions

Ligon, J. A., Wessel, K. M., Shah, N. N., & Glod, J. W. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.846346 · Cited by 16

Prospective approaches to enhancing CAR T cell therapy for glioblastoma

Choi, S. Y., & Yin, J. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1008751 · Cited by 16

New insights on potency assays from recent advances and discoveries in CAR T-cell therapy

Shao, L., Zheng, Y., Somerville, R. P. T., Stroncek, D. F., & Jin, P. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1597888 · Cited by 16

T-cell exhaustion in COVID-19: what do we know?

Chen-Camaño, R., DeAntonio, R., & López‐Vergès, S. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1678149 · Cited by 16

Chimeric antigen receptor T-cell therapy in childhood acute myeloid leukemia: how far are we from a clinical application?

Naik, S., Velasquez, M. P., & Gottschalk, S. M. (2024) · Haematologica · doi:10.3324/haematol.2023.283817 · Cited by 15

Harnessing the tumor microenvironment to boost adoptive T cell therapy with engineered lymphocytes for solid tumors

Spiga, M., Martini, E., Maffia, M. C., Ciceri, F., Ruggiero, E., Potenza, A., & Bonini, C. (2024) · Seminars in Immunopathology · doi:10.1007/s00281-024-01011-y · Cited by 16

RIG-I is an intracellular checkpoint that limits CD8+ T-cell antitumour immunity

Duan, X., Hu, J., Zhang, Y., Zhao, X., Yang, M., Sun, T., Liu, S., Chen, X., Feng, J., Li, W., et al. (2024) · EMBO Molecular Medicine · doi:10.1038/s44321-024-00136-9 · Cited by 15

IL-2–inducible T cell kinase deficiency sustains chimeric antigen receptor T cell therapy against tumor cells

Fu, Z., Huang, Z., Xu, H., Liu, Q., Li, J., Song, K., Deng, Y., Tao, Y., Zhang, H., Wang, P., et al. (2024) · Journal of Clinical Investigation · doi:10.1172/jci178558 · Cited by 18

CAR T-cell Therapy Meets Clonal Hematopoiesis

Uslu, U., & June, C. H. (2022) · Blood Cancer Discovery · doi:10.1158/2643-3230.bcd-22-0067 · Cited by 15

Epigenetic engineering for optimal chimeric antigen receptor T cell therapy

Ito, Y., & Kagoya, Y. (2022) · Cancer Science · doi:10.1111/cas.15541 · Cited by 14

Translational considerations for immunotherapy clinical trials in pediatric neuro-oncology

Foster, J., Alonso, M. M., Sayour, E. J., Davidson, T. B., Persson, M. L., Dun, M. D., Kline, C., Mueller, S., Vitanza, N. A., & van der Lugt, J. (2023) · Neoplasia · doi:10.1016/j.neo.2023.100909 · Cited by 14

Insulin-like Growth Factor-1 Synergizes with IL-2 to Induce Homeostatic Proliferation of Regulatory T Cells

Shapiro, M. R., Peters, L. D., Brown, M. E., Cabello-Kindelan, C., Posgai, A. L., Bayer, A. L., & Brusko, T. M. (2023) · The Journal of Immunology · doi:10.4049/jimmunol.2200651 · Cited by 14

New epigenetic regulators of T cell exhaustion

Kissick, H. T., & Ahmed, R. (2022) · Cancer Cell · doi:10.1016/j.ccell.2022.06.008 · Cited by 14

Metabolization of microbial postbiotic pentanoate drives anti-cancer CAR T cellsPreprint

Staudt, S., Nikolka, F., Perl, M., Franz, J., Leblay, N., Yuan, X.-K., Larrayoz, M., Lozano, T., Warmuth, L., Fante, M. A., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.08.19.608538 · Cited by 18

Targeting epigenetic mechanisms of resistance to chemotherapy in gliomas

Skouras, P., Markouli, M., Papadatou, I., & Piperi, C. (2024) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2024.104532 · Cited by 13

Immune Checkpoint Inhibitor Therapy and Associations with Clonal Hematopoiesis

Singh, A., Mencia-Trinchant, N., Mishra, R., Arora, K., Mehta, S., Kuzmanovic, T., Nikoo, M. Z., Singh, I., Przespolewski, A., Swaminathan, M., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252011049 · Cited by 14

Challenges in the preclinical design and assessment of CAR-T cells

Tomai, R. A., Rivas, J. D. L., Fetică, B., Bergantim, R., Filipić, B., Gagić, Ž., Nikolic, K. M., Gulei, D., Kegyes, D., Nistor, M., et al. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1564998 · Cited by 14

Enhanced FOS expression improves tumor clearance and resists exhaustion in NR4A3-deficient CAR T cells under chronic antigen exposure

Yin, P., Yang, J.-G., Jiang, Y., Han, L., Xiong, T.-C., Liu, H., Fang, Y., Ruan, W., Wu, J., Chen, L., et al. (2025) · Science Advances · doi:10.1126/sciadv.adw3571 · Cited by 13

CAR-T Cells Shoot for New Targets: Novel Approaches to Boost Adoptive Cell Therapy for B Cell-Derived Malignancies

Marhelava, K., Krawczyk, M., Firczuk, M., & Fidyt, K. (2022) · Cells · doi:10.3390/cells11111804 · Cited by 14

Harnessing the potential of gene editing technology for CAR-T cell therapy of solid tumors

Khodabandehloo, E., Rayati, M., Ahmadi, E., Naghdibadi, M., Moradi, V., & Ahmadbeigi, N. (2025) · Inflammation and Regeneration · doi:10.1186/s41232-025-00398-x · Cited by 13

Epigenetics behind CD8+ T cell activation and exhaustion

Zu, H., & Chen, X. (2024) · Genes and Immunity · doi:10.1038/s41435-024-00307-1 · Cited by 13

Supercharging CAR-T cells through transcriptional and epigenetic armoring

Qin, D., Lei, Y., Shu, P., Zhang, Y., Loh, Y., Wang, Y., & Li, Q. (2025) · Theranostics · doi:10.7150/thno.107908 · Cited by 13

Evolving CAR T-Cell Therapy to Overcome the Barriers in Treating Pediatric Central Nervous System Tumors

Timpanaro, A., Song, E. Z., Emwas, N., Chiu, C.-H., Ronsley, R. J., Taylor, M. R., Foster, J., Wang, L. D., & Vitanza, N. A. (2025) · Cancer Discovery · doi:10.1158/2159-8290.cd-24-1465 · Cited by 12

Response to Immune Checkpoint Blockade Is Enhanced in the Presence of Hematopoietic TET2 Inactivation

Rondeau, V., Bansal, S., Buttigieg, M. M., Zeng, A. G. X., Chan, D. Y., Chan‐Seng‐Yue, M., Liqing, J., McLeod, J. L., Kates, M., Donato, E., et al. (2025) · Cancer Research · doi:10.1158/0008-5472.can-24-3329 · Cited by 12

Engineering enhanced chimeric antigen receptor-T cell therapy for solid tumors

Neeser, A., Ramasubramanian, R., Wang, C., & Ma, L. (2023) · Immuno-Oncology Technology · doi:10.1016/j.iotech.2023.100385 · Cited by 13

Chimeric Antigen Receptor-T Cell Therapy for Lymphoma: New Settings and Future Directions

Savelli, C. B., Clerico, M., Botto, B., Secreto, C., Cavallo, F., Dellacasa, C. M., Busca, A., Bruno, B., Freilone, R., Cerrano, M., et al. (2023) · Cancers · doi:10.3390/cancers16010046 · Cited by 13

Lysine methylation modifications in tumor immunomodulation and immunotherapy: regulatory mechanisms and perspectives

Luo, Y., Lu, J., Lei, Z., Zhu, H., Rao, D., Wang, T., Fu, C., Zhang, Z., Xia, L., & Huang, W. (2024) · Biomarker Research · doi:10.1186/s40364-024-00621-w · Cited by 12

Chimeric antigen receptor–modified T-cell therapy: Recent updates and challenges in autoimmune diseases

Caël, B., Bôle‐Richard, E., Garnache‐Ottou, F., & Aubin, F. (2024) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2024.12.1066 · Cited by 13

The mechanisms and countermeasures for CAR-T cell expansion and persistence deficiency

Bao, Y.-T., Lv, M., Huang, X., & Zhao, X. (2025) · Cancer Letters · doi:10.1016/j.canlet.2025.217771 · Cited by 11

Fine tuning towards the next generation of engineered T cells

Nguyen, T. T., Ho, P., Staudt, S., Grégoire, C., Ziegler-Martin, K., Jassin, M., Block, A., Hudecek, M., Melenhorst, J. J., Caers, J., et al. (2025) · Nature Biomedical Engineering · doi:10.1038/s41551-025-01492-8 · Cited by 11

Engineering second-generation TCR-T cells by site-specific integration of TRAF-binding motifs into the CD247 locus

Lah, S., Kim, S., Kang, I., Kim, H.-J., Hupperetz, C., Jung, H., Choi, H. R., Lee, Y.-H., Jang, H., Bae, S., et al. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-005519 · Cited by 12

Molecular and clinical aspects relevant for counseling individuals with clonal hematopoiesis of indeterminate potential

Cacic, A. M., Schulz, F. I., Germing, U., Dietrich, S., & Gattermann, N. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1303785 · Cited by 12

CAR T-cells for pediatric solid tumors: where to go from here?

Trautmann, T., Yakobian, N., & Nguyen, R. (2024) · Cancer and Metastasis Reviews · doi:10.1007/s10555-024-10214-6 · Cited by 10

Natural killer cells’ functional impairment drives the immune escape of pre-malignant clones in early-stage myelodysplastic syndromes

Rodríguez‐Sevilla, J. J., Gañán‐Gómez, I., Kumar, B., Thongon, N., Ma, F., Chien, K. S., Kim, Y. J., Yang, H., Loghavi, S., Tan, R., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-58662-0 · Cited by 10

B7-H3 CAR T Cells Are Effective against Ependymomas but Limited by Tumor Size and Immune Response

Mehta, S., Ippagunta, S. M., Varadharajan, S., Kardian, A., Laboe, N., Dinh, D., Jones, A. B., Meehl, M. M., Ibañez-Vega, J., Emanus, E., et al. (2025) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-24-3083 · Cited by 10

Applications of CRISPR Epigenome Editors in Tumor Immunology and Autoimmunity

Yahsi, B., Palaz, F., & Dinçer, P. (2024) · ACS Synthetic Biology · doi:10.1021/acssynbio.3c00524 · Cited by 10

Clonal hematopoiesis in people with advanced HIV and associated inflammatory syndromes

Rocco, J. M., Zhou, Y., Liu, N., Laidlaw, E., Galindo, F., Anderson, M. V., Rupert, A. W., Lage, S. L., Ortega‐Villa, A. M., Yu, S. J., et al. (2024) · JCI Insight · doi:10.1172/jci.insight.174783 · Cited by 10

CAR-T Therapy Beyond B-Cell Hematological Malignancies

Canichella, M., & de Fabritiis, P. (2025) · Cells · doi:10.3390/cells14010041 · Cited by 9

Two chemotherapeutic agents expand stem-like CD62L+CD8+ T cells in antitumor immune responses

Ruan, X., Wu, L., Tang, Z., Li, Y., Wang, J., Jiang, H., Zhang, L., Wang, S., Chen, Z., Yuan, C., et al. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1533857 · Cited by 10

TET Proteins in the Spotlight: Emerging Concepts of Epigenetic Regulation in T Cell Biology

Tsagaratou, A. (2023) · ImmunoHorizons · doi:10.4049/immunohorizons.2200067 · Cited by 9

Regulation and Immunotherapeutic Targeting of the Epigenome in Exhausted CD8 T Cell Responses

Ford, B. R., & Poholek, A. C. (2023) · The Journal of Immunology · doi:10.4049/jimmunol.2200681 · Cited by 9

Synthesizing a Smarter CAR T Cell: Advanced Engineering of T-cell Immunotherapies

Zhu, I., Piraner, D. I., & Roybal, K. T. (2023) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-22-0962 · Cited by 9

Plasma Cell-Free Tumor Methylome as a Biomarker in Solid Tumors: Biology and Applications

Sacdalan, D. B., Haq, S. U., & Lok, B. H. (2024) · Current Oncology · doi:10.3390/curroncol31010033 · Cited by 9

Genome editing approaches for universal chimeric antigen receptor T cells

Mishra, A. K., & Qasim, W. (2024) · EJC Paediatric Oncology · doi:10.1016/j.ejcped.2024.100149 · Cited by 9

Epigenetic landscapes drive CAR-T cell kinetics and fate decisions: Bridging persistence and resistance

Wang, K., Ou, K., Zeng, Y., Yue, C., Zhuo, Y., Wang, L., Chen, H., & Tu, S. (2025) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2025.104729 · Cited by 9

Gene editing technology to improve antitumor T-cell functions in adoptive immunotherapy

Ito, Y., Inoue, S., & Kagoya, Y. (2024) · Inflammation and Regeneration · doi:10.1186/s41232-024-00324-7 · Cited by 8

Decoding Clonal Hematopoiesis: Emerging Themes and Novel Mechanistic Insights

Pendse, S., & Loeffler, D. (2024) · Cancers · doi:10.3390/cancers16152634 · Cited by 8

Electrical Stimulation Generates Induced Tumor-Suppressing Cells, Offering a Potential Option for Combatting Breast Cancer and Bone Metastasis

Cui, C.-P., Xu, Y., Xiong, X., Aryal, U. K., Chen, A. B., Chien, S. Y.-P., You, L., Li, B., & Yokota, H. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26031030 · Cited by 8

Characterization of Rationally Designed CRISPR/Cas9-Based DNA Methyltransferases with Distinct Methyltransferase and Gene Silencing Activities in Human Cell Lines and Primary Human T Cells

Guerra-Resendez, R. S., Lydon, S. L., Ma, A. J., Bedford, G. C., Reed, D. R., Kim, S. H., Terán, E. R., Nishiguchi, T., Escobar, M., DiNardo, A. R., et al. (2025) · ACS Synthetic Biology · doi:10.1021/acssynbio.4c00569 · Cited by 10

Harnessing the potential of gene-editing technology to overcome the current bottlenecks of CAR-T cell therapy in T-cell malignancies

Ismail, A., Khormi, M. A., Mawkili, W., Albaqami, A., Areshi, S. M., Aborasain, A. M., Hegazy, M. M., Amin, A. H., & Abo-Zaid, M. A. (2025) · Experimental Hematology · doi:10.1016/j.exphem.2025.104762 · Cited by 9

Epigenetic priming as a driver of memory recall and dysfunction in T cells

Metzemaekers, M., Rinzema, N. J., & Stadhouders, R. (2025) · The Journal of Experimental Medicine · doi:10.1084/jem.20241433 · Cited by 8

Leveraging T cells for cancer immunotherapy

Bates, A., Fletcher, N. E., Gao, F., Pinho, M. P., & Dong, T. (2025) · Immunity & Inflammation · doi:10.1007/s44466-025-00007-z · Cited by 8

CRISPR/Cas strategies to enhance CAR T-cell function and persistence via metabolic reprogramming

Wang, M. R., Mu, W., Zhen, A., & Kitchen, S. G. (2026) · Trends in biotechnology · doi:10.1016/j.tibtech.2025.12.001 · Cited by 9

Novel chimeric antigen receptor‐expressing T cells targeting the malignant mesothelioma‐specific antigen sialylated HEG1

Kouro, T., Higashijima, N., Horaguchi, S., Mano, Y., Kasajima, R., Xiang, H., Fujimoto, Y., Kishi, H., Hamana, H., Hoshino, D., et al. (2024) · International Journal of Cancer · doi:10.1002/ijc.34843 · Cited by 8

The efficacy and applicability of chimeric antigen receptor (CAR) T cell-based regimens for primary bone tumors: A comprehensive review of current evidence

Barzegari, A., Salemi, F., Kamyab, A., Aratikatla, A., Nejati, N., Valizade, M., Eltouny, E., & Ebrahimi, A. (2024) · Journal of bone oncology · doi:10.1016/j.jbo.2024.100635 · Cited by 9

T Cell Defects: New Insights Into the Primary Resistance Factor to CD19/CD22 Cocktail CAR T-Cell Immunotherapy in Diffuse Large B-Cell Lymphoma

Wang, J., Shen, K., Mu, W., Li, W., Zhang, M., Zhang, W., Li, Z., Ge, T., Zhu, Z., Zhang, S., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.873789 · Cited by 9

Chimeric Antigen Receptor T-Cell Therapy and Hematopoiesis

Reinhardt, B., Lee, P. C., & Sasine, J. P. (2023) · Cells · doi:10.3390/cells12040531 · Cited by 9

Risk of Second Tumors and T-Cell Lymphoma after CAR T-Cell Therapy

Godfrey, J., Querfeld, C., & Song, J. (2024) · New England Journal of Medicine · doi:10.1056/nejmc2408733 · Cited by 8

Optimising CAR T therapy for the treatment of solid tumors

Mobark, N., Hull, C., & Maher, J. F. (2024) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2024.2421194 · Cited by 7

Clonal Hematopoiesis: Impact on Health and Disease

Caiado, F., & Manz, M. G. (2025) · Hematological Oncology · doi:10.1002/hon.70075 · Cited by 7

De novo DNA methylation programs regulate CAR T-cell exhaustion

Zebley, C. C., Petersen, C. T., Prinzing, B. L., Bell, M. R., Fan, Y., Crawford, J. C., Houke, H., Haydar, D., Yi, Z., Nguyen, P., et al. (2020) · The Journal of Immunology · doi:10.4049/jimmunol.204.supp.246.5 · Cited by 5

De novo DNA methylation programs regulate T cell exhaustion and limit T cell-based immunotherapies

Youngblood, B., Ghoneim, H. E., Abdelsamed, H. A., Moustaki, A., Fan, Y., Crawford, J. C., Thomas, P. G., Stewart, E. S., & Federico, S. M. (2019) · The Journal of Immunology · doi:10.4049/jimmunol.202.supp.134.14 · Cited by 3

CAR T cells need a pitstop to win the race

Zebley, C. C., & Youngblood, B. (2021) · Cancer Cell · doi:10.1016/j.ccell.2021.05.011 · Cited by 5

Abstract 61: Transient "rest" reinvigorates exhausted CAR T cells via epigenetic remodeling

Weber, E. W., & Mackall, C. L. (2021) · Cancer Research · doi:10.1158/1538-7445.am2021-61

Transient rest restores functionality in exhausted CAR-T cells through epigenetic remodeling

Weber, E. W., Parker, K. R., Sotillo, E., Lynn, R. C., Anbunathan, H., Lattin, J., Good, Z., Belk, J. A., Dániel, B., Klysz, D. D., et al. (2021) · Science · doi:10.1126/science.aba1786 · Cited by 653